Sanos Clinic completes extensive study in new phase 1 unit
Sanos Clinic’s facilities in Herlev were expanded in October 2021 with a unique unit focused exclusively on phase 1 studies. The first clinical study with more than 80 participants has already been successfully completed, and more are in the pipeline.
Sanos Clinic has conducted several Phase 2 and 3 studies since 2018 and now also offers Phase 1 studies in the recently opened unit in Herlev. The unit has the capacity to conduct four to six Phase 1 studies per year as part of the Sanos Group, which with more than 25 years as a clinical contract research organization (CRO) has contributed to bringing several drugs to market.
“The clinic meets the highest quality standards and offers an efficient trial environment with a sharp focus on the needs and safety of both sponsors and participants. Our research staff has built up extensive clinical experience and has completed several phase 1 to 3 studies. We use advanced methods to recruit patients through media campaigns, telephone dialogue and local outreach. This ensures rapid patient recruitment, high data quality and high safety for participants in the research projects,” says Group CEO Jeppe Ragnar Andersen, Sanos Group.
The Phase 1 unit in Herlev is staffed by a permanent staff of doctors, nurses, bioanalysts, radiographers and project secretaries, all of whom have experience with best clinical practice and conducting clinical studies. For particularly specialized tasks, Sanos Clinic has associated a network of specialists, including consulting physicians specializing in neurology and dermatology. The Phase 1 unit performs a wide range of clinical trials that are an immediate extension of the first-in-human stage, where they, with their experience in recruiting patients, can conduct studies in both patient populations and among volunteers.
Political focus on life science
“New medical treatments for patients with a great need for help rely on effective clinical studies that ensure scientific results and high-quality data within a manageable time horizon. This is where Sanos Group makes a difference, and we already have several phase 1 studies underway following the expansion of our clinic in Herlev,” says Jeppe Ragnar Andersen.
Developing drugs from idea to product can take up to ten years, and the first step on the way is testing the drugs in Phase 1 studies. There are only a few Phase 1 units in Denmark, and as part of an effort to strengthen the Danish life science industry, the government removed all fees for conducting Phase 1 studies in 2018.
Sanos Clinic’s new unit gives pharmaceutical and biotech companies and CROs better opportunities to test their products on Danish soil and contributes to securing Denmark a strong position in the global competition within life science and phase 1 studies. It is estimated that the global CRO market amounts to over USD 55 billion. with increasing investments in research and development of new drugs and treatments, just as more pharmaceutical and biotech companies are outsourcing clinical studies with new drugs to contract research organizations.
Unique contract research facilities
The Phase 1 unit in Herlev is flexibly designed with 10 adjustable beds, kitchen facilities and a lounge for studies requiring overnight stays. All clinics are equipped with modern medical equipment, including ultrasound, ECG, EEG, MRI, X-ray, DEXA scanners, etc. Each clinic also contains a dedicated laboratory for on-site analysis with -80°C freezer, centrifuge, hematology and urine analyzers, and point of care testing.
Sanos Clinic has three dedicated clinical research centers in Gandrup, Vejle and Herlev as part of Sanos Group, a leading specialized provider of clinical study services in the global pharmaceutical and biotechnology industry.
Further information can be obtained from:
Group CEO Jeppe Ragnar Andersen, Sanos Group: 7370 8223, jra@sanos.com